EGFRvIII is a key oncogene in glioblastoma (GBM). EGFRvIII results from an in-frame deletion in the extracellular domain of EGFR, does not bind ligand and is thought to be constitutively active. Although EGFRvIII dimerization is known to activate EGFRvIII, the factors that drive EGFRvIII dimerization and activation are not well understood. Here we present a new model of EGFRvIII activation and propose that oncogenic activation of EGFRvIII in glioma cells is driven by co-expressed activated EGFR wild type (EGFRwt). Increasing EGFRwt leads to a striking increase in EGFRvIII tyrosine phosphorylation and activation while silencing EGFRwt inhibits EGFRvIII activation. Both the dimerization arm and the kinase activity of EGFRwt are required for EGFRvIII activation. EGFRwt activates EGFRvIII by facilitating EGFRvIII dimerization. We have previously identified HB-EGF, a ligand for EGFRwt, as a gene induced specifically by EGFRvIII. In this study, we show that HB-EGF is induced by EGFRvIII only when EGFRwt is present. Remarkably, altering HB-EGF recapitulates the effect of EGFRwt on EGFRvIII activation. Thus, increasing HB-EGF leads to a striking increase in EGFRvIII tyrosine phosphorylation while silencing HB-EGF attenuates EGFRvIII phosphorylation, suggesting that an EGFRvIII-HB-EGF-EGFRwt feed-forward loop regulates EGFRvIII activation. Silencing EGFRwt or HB-EGF leads to a striking inhibition of EGFRvIII-induced tumorigenicity, while increasing EGFRwt or HB-EGF levels resulted in accelerated EGFRvIII-mediated oncogenicity in an orthotopic mouse model. Furthermore, we demonstrate the existence of this loop in human GBM. Thus, our data demonstrate that oncogenic activation of EGFRvIII in GBM is likely maintained by a continuous EGFRwt-EGFRvIII-HB-EGF loop, potentially an attractive target for therapeutic intervention.
INTRODUCTION
Aberrant receptor tyrosine kinase (RTK) signaling has a key role in glioblastoma(GBM). [1] [2] Although increased expression of other RTKs such as PDGFRA is detected in GBMs, 3 EGFR gene amplification and mutation are the most striking abnormality detected in about 40-50% of patients with GBM and usually found in the classical subtype of GBM. 2 In about 50% of tumors with EGFR amplification, a specific EGFR mutant (EGFR Type III, EGFRvIII, de2-7, DEGFR) can be detected. [4] [5] EGFRvIII is generated from a deletion of exons 2-7 of the EGFR gene, which results in an in frame deletion of 267 amino acids. EGFRvIII is unable to bind ligand and signals constitutively. As EGFRvIII is a tumor-specific EGFR mutant, it has attracted intense interest both for its potential role in the biology of GBM, as well as a target for treatment. [5] [6] Anti-EGFR treatment with EGFR specific kinase inhibitors appears to be less successful in GBM compared with lung cancer, possibly secondary to altered kinetics of inhibitor binding or sensitivity of EGFRvIII compared with EGFR mutants in lung cancer. [7] [8] A number of studies have demonstrated that the EGFRvIII is more tumorigenic than the EGFR wild type (EGFRwt). [9] [10] [11] [12] EGFRvIII does not bind ligand, becomes tyrosine phosphorylated and appears to signal constitutively when expressed in cells. 13 Dimerization of EGFRvIII has an important role in its activation. [14] [15] [16] [17] EGFRvIII may homodimerize or heterodimerize with the EGFR. We and others have reported biologically significant interactions between EGFRwt and EGFRvIII in glioma, suggesting that key effector signals from EGFRvIII require participation of EGFRwt. [18] [19] These studies have provided evidence of EGFRvIII-induced autocrine or paracrine loops in GBM mediated by RTK ligands such as HB-EGF 18 or cytokines such as IL6, 19 or heterodimerization between the receptors. 16 Such interactions have the potential to profoundly alter the biological outcome of EGFRvIII signaling.
In this study, we show that EGFRwt activates EGFRvIII and is required for EGFRvIII to exert its oncogenic effect in glioma cells. Thus, when EGFRwt is silenced, tyrosine phosphorylation of EGFRvIII is highly attenuated. Conversely, increasing the EGFRwt level results in amplified EGFRvIII activation. Examination of the transcriptional program of EGFRvIII in the presence or absence of EGFRwt led to the identification of heparin-binding epidermal growth factor (HB-EGF)-like growth factor, which is induced by EGFRvIII only in the presence of EGFRwt. HB-EGF is a ligand for EGFRwt and, remarkably, altering HB-EGF recapitulates the effect of EGFRwt on EGFRvIII tyrosine phosphorylation/activation and oncogenicity. Importantly, we find that the EGFRwt is an important partner for EGFRvIII in promoting the malignant phenotype. Thus, silencing EGFRwt or HB-EGF in EGFRvIII-expressing glioma cells severely inhibits tumor formation, while increased expression of EGFRwt or HB-EGF in EGFRvIII-expressing cells accelerates tumor formation. Thus, we propose that EGFRvIII is activated by co-expressed EGFRwt, which is activated in turn, by HB-EGF induced by EGFRvIII in a feed-forward loop.
RESULTS

EGFRwt influences activation of EGFRvIII
EGFRwt and EGFRvIII are usually co-expressed in GBMs. To investigate the role of EGFRwt in EGFRvIII signaling, we used U251MG cells to conditionally express EGFRvIII in response to tetracycline (U251vIII cells, Figure 1a ) as described previously. 18 Next, we selectively and stably silenced endogenous EGFRwt but not EGFRvIII in U251vIII cells by using two different shRNA sequences directed against exon 3. We generated two clones with selective silencing of EGFRwt designated U251vIII-5 and U251vIII-2 (also referred to as clone 5 or 2), along with a control with scrambled shRNA (Figures 1b and i) . U251vIII-5 has more efficient silencing of EGFRwt compared with U251vIII-2. In addition, we generated U251vIII clones constitutively overexpressing a hemagglutinin (HA)-tagged EGFRwt designated as U251vIII-15 and U251vIII-18 (clone 15 and 18) as shown in Figures 1c, d , e and i. Thus, we generated U251EGFRvIII-expressing cell lines that conditionally express EGFRvIII in response to tetracycline on a background of overexpressed EGFRwt 15 and 18, endogenous EGFRwt (control) and silenced EGFRwt 2 and 5. EGFRvIII expression induced by tetracycline is similar in all lines.
We find that the level of EGFRwt has a profound effect on tyrosine phosphorylation of EGFRvIII. As can be seen in Figure 1f , there is a striking increase in tyrosine phosphorylation of EGFRvIII in U251vIII-15 cells whereas tyrosine phosphorylation of EGFRvIII is significantly attenuated in U251vIII-5 cells and intermediate in control cells (Figure 1f) . A similar result was found in a second clone overexpressing EGFRwt or with EGFRwt silenced (Supplementary Figure 1a) . Constitutive overexpression of EGFRwt results in a low level of activation/tyrosine phosphorylation of EGFRwt (Figure 1f and Supplementary Figure 1a and b), consistent with previous observations. [20] [21] The phospho-EGFR antibody used first in this experiment is directed against tyrosine 1068 of the EGFR. We confirmed a similar increase in phosphorylation of EGFRvIII in EGFRvIII-15 cells using phospho-EGFR antibodies directed against Tyrosine 1173 and Tyrosine 845 (Figure 1f ), but not in U251vIII-5 or U251vIII-control cells. This may reflect the sensitivity of the antibodies used and/or the need for a high level of EGFRwt for EGFRvIII to become phosphorylated at these residues. Furthermore, transient overexpression of EGFRwt-HA in U87-vIII cells also results in increased phosphorylation of EGFRvIII (Figure 1g ). The level of EGFRvIII expression in U87-vIII and U251-vIII cells is similar to GBM tumors (Figure 1h) . A table describing the various U251MG-EGFRvIII clones used is presented in Figure 1i . Next, we examined a panel of primary GBM neurosphere cultures and found two tumors, GBM9 and GBM748, that retain EGFRvIII expression (Figure 2a ). GBM748 with EGFRwt overexpression, has increased EGFRvIII phosphorylation compared with GBM9 expressing a low level of EGFRwt (Figure 2b ). Transient overexpression of EGFRwt-Myc results in increased EGFRvIII tyrosine phosphorylation in GBM9 cells (Figure 2c ). Furthermore, selective silencing of EGFRwt results in decreased tyrosine phosphorylation of EGFRvIII compared with control siRNA (Figure 2d ). Thus, EGFRwt regulates EGFRvIII activation in established GBM lines as well as in primary GBM neurosphere cultures.
Next, we transiently transfected epitope-tagged EGFRwt-Myc and EGFRvIII-HA in COS-7 cells. EGFRvIII phosphorylation is substantially increased by co-expression of EGFRwt-Myc in whole cell lysates (Supplementary Figure 1b) and by immunoprecipitation of EGFRvIII using HA antibodies. In order to eliminate any contribution of co-immunoprecipitating EGFRwt, we denatured lysates prior to immunoprecipitation. As shown in Figure 2e , co-expression of EGFRwt induces a substantial increase in EGFRvIII tyrosine phosphorylation. Surprisingly, exposure to exogenous EGF does not increase EGFRvIII phosphorylation, and seems to decrease it in COS cells suggesting that a low level of EGFRwt activation is optimal for EGFRvIII activation. Furthermore, transient silencing of endogenous EGFRwt in COS-7 cells results in a significant decrease in phosphorylation of transfected EGFRvIII (Figure 2f ). It should be noted that the EGF-induced dephosphorylation of EGFRvIII is not detected in glioma cells 43 , so there may be cell-type-specific differences.
EGFRwt-induced activation of EGFRvIII requires both the kinase activity and the dimerization loop of EGFRwt Binding of ligand to the extracellular domain of EGFRwt leads to its dimerization and activation of the tyrosine kinase activity of the receptor. [22] [23] Dimerization appears to have a key role in EGFR activation and internalization. The CR1 region in the extracellular domain of the EGFRwt is known to have an essential role in dimerization of the EGFR. [24] [25] We transiently transfected EGFRwt, EGFR kinase mutant or an EGFR dimerization loop mutant (CR1) along with EGFRvIII-HA into COS cells and find that both the kinase activity of EGFRwt and its dimerization loop are required for inducing EGFRvIII phosphorylation as shown in Figure 2g .
EGFRwt facilitates dimerization of EGFRvIII but does not transphosphorylate EGFRvIII
Transfection of an EGFRvIII kinase-inactive mutant HA into COS cells along with EGFRwt-Myc was followed by immunoprecipitation with HA antibody and western blot with pEGFR antibodies. No phosphorylation of EGFRvIII-kinase mutant can be detected although there is robust phosphorylation of the kinase-intact EGFRvIII mutant (Figure 2h ). This result argues against EGFRwt transphosphorylating EGFRvIII. Next, we examined the influence of EGFRwt on EGFRvIII dimerization by using a cross-linker, BS 3 . U251vIII-15 and U251vIII-5 cells were exposed to tetracycline to induce EGFRvIII expression. Dimerization of EGFRvIII is significantly amplified in U251vIII-15 compared with U251vIII-5 cells (Figure 2i ). In addition, by co-transfecting EGFRvIII-HA and EGFRwt-Myc into COS-7 cells, we find that EGFRvIII and EGFRwt form a physical complex (Figure 2j ). Thus, our data suggest that EGFRwt promotes EGFRvIII phosphorylation by facilitating dimerization of EGFRvIII. Table 1 ). Ingenuity pathway analysis revealed that the top canonical pathway induced by EGFRvIII expression in control and U251vIII-15 cells, but not in U251vIII-5 cells, is the 'role of tissue factor in cancer' a network of oncogenic ligands such as HB-EGF and IL-8. 26 Remarkably, under conditions of maximal EGFRvIII activation in U251vIII-15 cells, EGFRvIII induced the activation of three EGFRwt ligands (HB-EGF, TGFA and BTC), whereas two ligands are induced in control cells and none in U251vIII-5 cells (Figure 3a) . Figure 3b shows upregulation of HB-EGF by EGFRvIII in U251vIII-15 cells and U251vIII-control cells but not in U251vIII-5 cells. An ELISA was performed to examine protein levels of HB-EGF and the results are similar to the quantitative PCR (qPCR) results (Supplementary Figure 3a) . HB-EGF was also induced in U87MG cells by EGFRvIII (Supplementary Figure 3b) . Confirmation of EGFRvIII-mediated induction of TGF-alpha and IL-8 by qPCR is shown in Supplementary Figures 3c and d. HB-EGF induces EGFRvIII activation Next, we stably silenced HB-EGF in U251EGFRvIII cells using lentiviral shRNA. Two clones with HB-EGF stably silenced were identified (Figure 3c ). We confirmed HB-EGF silencing at a protein level by conducting an ELISA (Supplementary Figure 3e) . We also generated lines stably overexpressing Myc-tagged-HB-EGF in U251vIII cells (Figure 3d ). Importantly, increased expression of HB-EGF results in a striking increase in tyrosine phosphorylation of EGFRvIII while silencing HB-EGF inhibits tyrosine phosphorylation of EGFRvIII ( lead to substantially increased dimerization of EGFRvIII compared with cells with silenced HB-EGF ( Figure 4a) .
Next, we investigated whether EGFRvIII leads to EGFRwt activation. We examined tyrosine phosphorylation of EGFRwt-HA in U251vIII-15 cells with or without tetracycline, by immunoprecipitating EGFRwt using HA antibodies followed by immunoblotting with pEGFR antibodies. Figure 4b shows an increased phosphorylation of EGFRwt when EGFRvIII is expressed. A similar result is detected in COS-7 cells (Figure 4c ). Importantly, a neutralizing EGFR antibody (528) that inhibits ligand binding to the EGFRwt attenuates activation of EGFRvIII (Figure 4d ) in U251vIII-15 cells and in COS cells (Figure 4e ). Similarly, a neutralizing antibody to HB-EGF inhibits EGFRvIII and EGFRwt tyrosine phosphorylation in U251vIII-15 cells (Figure 4f ). These findings strongly suggest that that an EGFRwt-EGFRvIII-HB-EGF feed-forward loop regulates activation of EGFRvIII. (g) GBM9 cells were transfected with HB-EGF siRNA followed by preparation of lysates after 72 h and western blot. As a control (C) we used scrambled (non-sequence siRNA). A part of this figure is also shown in Figure 2d . (h) HB-EGF silencing was confirmed with quantitative realtime PCR. A two-tailed t-test was statistically significant (Po0.0001). The pEGFR antibody used in experiments in this figure was Tyr-1068. Gene expression analysis was performed with two replicates and a change of twofold or greater was considered significant. U251vIII-15 cells were exposed to tetracycline with or without EGF followed by immunoprecipitation with HA antibodies. The tyrosine-phosphorylated band aligns perfectly with the tyrosine-phosphorylated band in the EGF-treated lane indicating that it is EGFRwt. (c) EGFRvIII-mediated activation of EGFRwt is demonstrated by co-transfecting COS-7 cells with EGFRwt-Myc and EGFRvIII-HA followed by denaturing lysates and IP with Myc antibody. The tyrosine phosphorylation of EGFRwt is amplified when EGFRvIII-HA is co-transfected. (d) Activation of EGFRvIII is attenuated by using an EGFR antibody (528) that inhibits ligand binding to EGFRwt. In the right lane, cells were exposed to EGF in the absence of tetracycline (no EGFRvIII) and show the position of the slower migrating pEGFRwt band. (e) COS-7 cells were transfected with EGFRvIII-HA þ EGFRwt-Myc or empty vector (v) followed by incubation with EGFR neutralizing antibody (528) or isotype matched control antibody. A phospho-EGFR (1068) antibody was used. (f ) HB-EGF neutralizing antibodies result in attenuation of both EGFRwt and EGFRvIII phosphorylation in U251vIII-15 cells while normal goat antibody has no effect. (g) Analysis of EGFRvIII-induced signal transduction in U251vIII-15, U251vIII-5 and U251vIII-control cells shows that ERK activation is equal in all clones, while Met activation is amplified in U251vIII-15 cells and attenuated in U251vIII-5 cells. Note that in the absence of tetracycline constitutive EGFRwt overexpression in EGFRvIII-15 cells results in increased Met phosphorylation. (h) Phospho-specific antibody microarrays comparing the effects of tetracycline-induced expression of EGFRvIII in U251vIII-15 cells to U251vIII-5 cells. There is a substantial increase in the phosphorylation of multiple RTKs (including EGFRvIII) in response to EGFRvIII expression in U251vIII-15 þ tet compared with U251vIII-5 þ tet cells. Two independent experiments were performed for h.
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EGFR activation levels influence MET and other RTK phosphorylation There is no difference in ERK activation in U251vIII-15 compared with U251vIII-5, suggesting that a low level of EGFRvIII activation is sufficient to activate ERK (Figure 4g ). EGFRvIII can transactivate the tyrosine kinase Met and other RTKs. [27] [28] [29] When EGFRvIII is expressed using tetracycline, there are significantly larger increases in Met phosphorylation in EGFRvIII-15 cells compared with EGFRvIII-5 cells (Figure 4g) . Furthermore, there is increased transactivation of other RTKs such as IR, IGF1R, AXL, RET and EPHA2 in U251vIII-15 cells compared with U251vIII-5 cells as detected by a phospho-specific antibody microarray (Figure 4h ).
EGFRwt and HB-EGF influence EGFRvIII-mediated oncogenicity in vivo
It has been reported that EGFRvIII does not have a significant effect on proliferation of glioma cells in culture, but profoundly influences oncogenicity in vivo. 9 We also did not find a significant influence of EGFRwt levels on the proliferation of EGFRvIIIexpressing cells in monolayer culture (Supplementary Figure 5a) . Next, we tested the cell lines for growth in an orthotopic xenograft model of GBM in nude mice. First, we confirmed that doxycycline penetrated into brain tumors by examining expression of EGFRvIII in lysates from mouse brain tumors implanted with U251-vIII cells (Figure 5a ). Subsequently, we implanted U251vIII-5, U251vIII-15 and U251vIII-control shRNA cells intracranially in nude mice and provided doxycycline in food and water. Kaplan-Meier survival analyses revealed that the U251vIII-5 mice remained symptomfree for a significantly longer period of time than the U251vIII-15 mice, while the U251vIII-15 mice formed tumors faster compared with the control mice (Figure 5b) . We repeated the experiment with EGFRvIII-5 cells in a second group of mice with a very similar result (Supplementary Figure 6a) . Hematoxylin and eosin sections from representative brains are shown in Figure 5d . EGFRwt and EGFRvIII levels in representative tumors are shown in Figure 5c . Three out of eight mice in the EGFRvIII-5 group formed tumors after long latencies while five mice did not form tumors, whereas all mice in control and EGFRvIII-15 groups formed tumors. In the three EGFRvIII-5 tumors EGFRvIII and EGFRwt levels are very high, presumably due to multiple rounds of selection for high EGFRexpressing cells (Figure 5c) . A second clone with less-complete EGFRwt silencing, U251vIII-2 also forms tumors after a longer latency compared with control. Thus, increasing the EGFRwt level accelerates the tumorigenicity of EGFRvIII while silencing EGFRwt inhibits tumor formation by EGFRvIII. The oncogenic effect of EGFRwt alone 30 is weaker and resulted in tumor formation in 102 days compared with 64 days for EGFRvIII (control group) (Supplementary Figure 6b) .
Next, we examined if altering HB-EGF has an effect on EGFRvIIImediated tumorigenicity. Although there was no difference in the proliferation of HB-EGF altered cells in culture ( Supplementary  Figure 5b) , we did note a significant difference in tumor growth in the orthotopic model. Kaplan-Meier survival analyses revealed that the Clone 50 mice (HB-EGF silenced) remained symptom-free for a significantly longer period of time than the Clone 34 mice (HB-EGF overexpressed) as shown in Figure 6a . Four out of eight mice in the Clone 50 group formed tumors after a long latency whereas all mice formed tumors in the Clone 34 group faster than the control group. Figure 6b shows hematoxylin and eosin sections of representative tumors or normal brain (Clone 50). The Myc-tagged HB-EGF can be detected in lysates from mouse tumors as shown in Figure 6c . Thus, the results of altering HB-EGF on EGFRvIII-induced tumorigenicity are similar to the effect of altering EGFRwt.
EGFR and HB-EGF expression in GBM Next, we assessed the presence of EGFRwt and EGFRvIII by western blots in tumor lysates made directly from GBM tissue (Figure 7a ). EGFRvIII mRNA levels were also detected by Figure 7b) . In this series of GBMs, 36% of tumors express both EGFRwt and EGFRvIII. Although EGFRwt is expressed in tumors without EGFRvIII, EGFRvIII was detected only in GBMs that have co-expression of EGFRwt. The presence of HB-EGF was detected by qPCR and a twofold increase in HB-EGF levels was deemed positive (Figures 7b-d) . Thus, a statistically significant correlation between the presence of EGFRvIII and HB-EGF expression in GBMs was noted (Figure 7e  and Supplementary Table 2 ). HB-EGF protein levels were also determined by ELISA in eight tumors (Supplementary Figure 7a) and the results are consistent with the qPCR data. These data show that the components of the EGFRvIII-HB-EGF-EGFRwtEGFRvIII feed-forward loop can be detected in GBM.
DISCUSSION
EGFRvIII is a prime oncogene in GBM. EGFRvIII does not bind any EGFR ligand and it has thus been assumed that EGFRvIII signals constitutively. Here, we propose that oncogenic activation of EGFRvIII in glioma cells is driven by co-expressed EGFRwt activated by ligands such as HB-EGF. Previous studies and our data show that increased expression of EGFRwt is sufficient to induce a low-level tyrosine phosphorylation of EGFRwt. We propose that the activated EGFRwt then promotes EGFRvIII activation and tyrosine phosphorylation. Furthermore, EGFRvIII contributes to its own activation by inducing expression of HB-EGF, a ligand for EGFRwt. Thus EGFRvIII activation is amplified by a positive feedback loop involving EGFRwt-EGFRvIII-HB-EGF-EGFRwt.
We present several lines of evidence demonstrating that EGFRwt has a critical role in EGFRvIII activation. Silencing EGFRwt in cells expressing EGFRvIII inhibits tyrosine phosphorylation of EGFRvIII and confers a loss of tumorigenicity in vivo, while overexpression of the EGFRwt results in a striking increase in EGFRvIII activation/tyrosine phosphorylation and rapid tumor growth in vivo in an orthotopic model. Furthermore, EGFRvIII induces expression of HB-EGF and other EGFRwt ligands. Remarkably, altering HB-EGF recapitulates the EGFRwt phenotype. Thus, increased expression of HB-EGF also leads to increased EGFRvIII tyrosine phosphorylation and tumorigenicity while silencing HB-EGF markedly inhibits EGFRvIII/activation tyrosine phosphorylation and tumorigenicity. Furthermore, EGFRvIII activation is attenuated by neutralizing antibodies to EGFR or HB-EGF. Consistent with our feed-forward model, EGFRvIII expression also leads to activation of EGFRwt and this activation can also be blocked by a neutralizing antibody to EGFRwt or HB-EGF. Our model is also supported by a previous study showing that an EGFR antibody (528) that inhibits binding of ligand to EGFRwt inhibits EGFRvIII-mediated tumor growth in xenograft studies. 31 EGFRwt ligands including HB-EGF and TGF-alpha are expressed in GBM. 18, [32] [33] We also find that EGFRwt, EGFRvIII and HB-EGF are commonly co-expressed and that EGFRvIII expression correlates with a high expression of HB-EGF.
EGFRvIII is expressed primarily in GBMs with EGFR gene amplification and overexpression of EGFRwt making it likely that the genetic abnormalities underlying overexpression of EGFRwt and EGFRvIII co-exist in individual tumor cells [34] [35] (Figure 7 ). Immunohistochemical studies comparing EGFRwt and EGFRvIII expression by immunohistochemistry using antibodies that are specific to EGFRwt and EGFRvIII suggest that EGFRwt and EGFRvIII expression commonly overlap. 34, 36 Nishikawa et al. found that in GBMs in which EGFRwt was detected almost all tumor cells expressed EGFRwt while the distribution of EGFRvIII was scattered in 65% of the tumors. These studies suggest that while in some GBMs the distribution of EGFRvIII may be more restricted compared with EGFRwt, 36 EGFRvIII is almost always expressed in EGFRwtexpressing cells. Another study recently reported similar findings. 37 Thus, all of the available data demonstrates that EGFRvIII is usually co-expressed with EGFRwt in the same GBM cells.
We have previously identified HB-EGF as a gene induced by EGFRvIII and hypothesized that an autocrine loop extends from EGFRvIII to EGFRwt. 38 In the current study, we show that the primary function of this loop is to activate EGFRvIII. Thus, we show by both loss-of-function and gain-of-function studies that HB-EGF and EGFRwt critically influence EGFRvIII activation and tumorigenicity. The EGFRvIII-EGFRwt interplay in GBM may involve multiple mechanisms in GBM including EGFRvIII-induced paracrine activation of EGFRwt. 19 Our results further suggest that the best experimental model for studying EGFRvIII signaling is one in which both receptors are co-overexpressed similar to that in GBM, as EGFRvIII in a background of high EGFRwt is highly activated.
Is EGFRwt absolutely required for EGFRvIII activation? Previous studies have shown that EGFRvIII becomes tyrosine phosphorylated in immortalized fibroblasts, Chinese hamster ovary cells and hematopoietic cells that do not express EGFRwt and can even transform immortalized fibroblasts, 14, 17, [39] [40] arguing against an absolute requirement of EGFRwt for activation of EGFRvIII. Our data demonstrate that in glioma cells if the EGFRwt level is low (we have not been able to completely silence EGFRwt), EGFRvIII activation is low and EGFRvIII loses it oncogenicity, whereas EGFRvIII activation is amplified and oncogenicity enhanced if EGFRwt is overexpressed. Thus, we conclude that EGFRwt has an important role in oncogenic activation of EGFRvIII in glioma cells.
Forced dimerization of EGFRvIII results in stronger activation and enhanced oncogenicity of EGFRvIII. 17 We show that increased EGFRwt or HB-EGF promotes EGFRvIII dimerization. The resultant increased activation of EGFRvIII leads to increased transactivation of multiple RTK families such as Met and EphA2 that may mediate the increased oncogenicity detected in vivo. Structurally, the EGFRvIII has a deletion of the extracellular amino acids 6-273 that constitute the dimerization arm and a part of the ligand-binding domain. Despite the lack of the dimerization arm, it is known that EGFRvIII is able to dimerize with EGFRwt. 16 Our data indicate that the dimerization arm of EGFRwt has a key role in EGFRvIII activation (Figure 2g ).
Previous studies have shown that EGFRwt and EGFRvIII can heterodimerize, and we also detect the formation of a physical complex between EGFRwt and EGFRvIII. Moreover, it appears that a low level of EGFRwt activation is optimal for EGFRvIII activation. Surprisingly, addition of exogenous EGF did not result in increased EGFRvIII activation, while overexpression of HB-EGF facilitates EGFRvIII activation. An important role for endogenous HB-EGF is suggested by experiments showing attenuated EGFRvIII phosphorylation with HB-EGF neutralizing antibodies or if HB-EGF is silenced.
We propose that the EGFRwt-EGFRvIII-HB-EGF feed-forward loop is a key regulatory network in GBM that maintains continuous activation and oncogenicity of EGFRvIII. These findings have implications for our understanding of EGFRvIII function and for therapeutic approaches to target the EGFR signaling system in GBM. The likely relevance of this model to human GBM is supported by data demonstrating a significant correlation between the expression of EGFRwt, EGFRvIII and HB-EGF components in human GBM samples. Although we have focused on HB-EGF in this study, EGFRvIII appears to induce additional EGFRwt ligands such as TGF-alpha and betacellulin, which may also participate in this feed-forward loop. This feed-forward loop may be an attractive target for GBM therapy.
MATERIALS AND METHODS
Plasmids, transfection and generation of cell lines U251MG and U87MG were used to generate cell lines conditionally expressing either EGFRwt or EGFRvIII using the T-Rex Tet-on system from Invitrogen (Carlsbad, CA, USA) as described previously. 18 EGFRwt-HA in PcDNA 3.1 (Neo) was transfected into U251EGFRvIII-expressing cells followed by selection of Supplementary table clones with G418. Lipofectamine 2000 (Invitrogen) was used for all transfections. Primary GBM cultures were generated directly from human GBM tumor specimens. Cells were cultured in Neurobasal medium supplemented with B27 without Vitamin A, and with EGF (10 ng/ml) and bFGF (10 ng/ml). GBM9 cells were a kind gift of Dr James Van Brocklyn. 41 COS-7 cells were transfected with equal amounts of DNA with empty vector or 5 ug of EGFRwt-Myc and/or 5 ug of EGFRvIII-HA for 48 h. Three independent experiments were performed unless specified otherwise.
RNA interference
We used a pool of siRNA sequences directed against exons 3-6 of the EGFRwt obtained from Qiagen (Valencia, CA, USA) (catalog no. S100300104) according to the manufacturer's protocol. For stable silencing of EGFRwt two different shRNA sequences targeting sequences within exons 2-7 cloned into pSilencer 3.1-H1 neo vector (Ambion, Grand Island, NY, USA) were obtained from Dr Stephen Lee (University of Ottawa, Canada) 42, 43 or control shRNA was used. HB-EGF was silenced using lentiviral shRNA particles from Santa Cruz Biotechnology (Dallas, TX, USA) (sc-39421-V) and puromycin selection.
Antibodies and phospho-specific antibody microarray A phospho-specific Proteome-Profiler RTK antibody microarray from R&D Systems (Minneapolis, MN, USA) was used. EGFR antibody was purchased from Millipore (Billerica, MA, USA). b-actin and EGFR neutralizing antibodies (528) were from Santa Cruz Biotechnology. Phospho-EGFR antibodies (Tyr-1068, Tyr-845, Tyr-1173), pERK, ERK, HA, Myc, pMet and Met antibodies were obtained from Cell Signaling Technology (Danvers, MA, USA). HB-EGF neutralizing antibody (AF-259-NA) was obtained from R&D Systems.
Dimerization assay BS 3 (bis[sulfosuccinimidyl] suberate) was obtained from Thermo Scientific (Waltham, MA, USA) and used according to the manufacturer's instructions. Cells were incubated with BS 3 (2 mM) at room temperature for 30 min followed by quenching and western blot.
Microarray analysis
Cells were incubated with or without tetracycline followed by RNA extraction. The Illumina humanHT-12 v4 Expression BeadChip (Illumina, San Diego, CA, USA) was used using the manufacturer's protocol. Significantly altered genes (fold change 42 or o À 2 with P-value o0.1) were further analyzed using the Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Inc., Redwood City, CA, USA) for enrichment analyses.
cDNA synthesis and real-time PCR cDNA synthesis and real-time PCR were performed as we have described previously. 18 Primer sequences are available upon request.
Primary tumors
Frozen tissue specimens of human GBMs were obtained according to institutional review board-approved protocols. Resected tumors were initially frozen at À 80 1C.
Cell proliferation assays
Cells were plated at 20 000 per well in a 12-well tissue culture plate in the presence and absence of tetracycline (1 mg/ml). The cells were trypsinized and counted using an automated cell counter after 72 h.
Orthotopic implants 2 Â 10 6 U251MG derived cells were suspended in PBS and matrigel (5 ml) and injected into the right corpus striatum of the brains of 6-8-week-old nude mice using a stereotactic frame. Animals were monitored and sacrificed when neurological signs appeared or after 240 days. All animal studies were done under Institutional Animal Care and Use Committeesapproved protocols.
HB-EGF ELISA HB-EGF ELISA was performed using an HB-EGF ELISA kit from R&D Systems (DY259) according to the manufacturer's protocol.
Statistical analysis
Error bars represent the means±standard deviations of three independent experiments. All data were analyzed for significance using GraphPad Prism 5.0 software, where Po0.05 was considered statistically significant. Oneway ANOVA and two-tail t-test were used to compare groups. Survival analysis for mice is described in the results and figure legends.
